ALTG 16/004 SCRIBE: A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastases – P Mitchell

This study examines nivolumab in combination with radiotherapy and the activity of nivolumab in combination with ipilimumab in SCLC brain metastases. Planned recruitment is 53 patients at 16 sites. The protocol is finalised and funding agreed with Bristol-Myers Squibb. Feasibility was circulated April 2017; central ethics submission is planned in May 2017 and FPI is expected Q4 2017.

Contact: SCRIBE@ctc.usyd.edu.au

Upcoming Events

28 August 2017 12.00am TACT Board Teleconference (closed)
8 September 2017 12.00am ESMO 2017 Congress, Madrid Spain
6 October 2017 12.00am ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC
15 October 2017 12.00am TACT General Assembly (closed), Yokohama Japan
15 October 2017 12.00am 18th WCLC, Yokohama Japan
24 November 2017 12.00am ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW
24 November 2017 12.00am ***UPDATED*** ALTG Members’ Meeting, Sydney NSW